RECCE® 327 Gel | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

27,313 results for “RECCE® 327 Gel”

Trials

View all 21851 →

CT 327 in the "Atopy Patch Test" Model

20 participants · First posted Jun 7, 2011

CT 327 in the Treatment of Psoriasis Vulgaris

58 participants · First posted Oct 16, 2009

CT 327 in the Treatment of Atopic Dermatitis

15 participants · First posted Oct 16, 2009

Drugs

View all 2019 →

R-327

RECCE-435

RECCE 529

Organizations

View all 117 →

RECCE PHARMACEUTICALS LTD

Australia

Sol-Gel Technologies

Israel

Sol-Gel Technologies, Inc.

United States

News

View all 3326 →

Recce Pharmaceuticals' R327G Shows Promise in Phase II ABSSSI Trial

Recce Pharmaceuticals' R327G Shows Promise in Phase II ABSSSI Trial

Recce Pharmaceuticals' Phase II Trial of RECCE® 327 Topical Gel Nears Completion with Positive Interim Results

Page 1 of 2732